Challenging the century-old norms of radiation therapy, Leo Cancer Care has closed a $65.0M Series d funding round. The company is developing a novel approach that positions patients upright and removes bulky gantries, aiming to improve treatment quality and significantly increase access to cancer care globally.
Founded in Australia, Leo Cancer Care's technology is built on extensive global research, shifting the focus from machine rotation to patient rotation. While its products are not yet commercially available, the capital will support its ongoing efforts towards FDA approval and CE mark, bringing its vision of more patient-centric and accessible treatments closer to reality.
